June 18 (Reuters) - Pfizer Inc and Sangamo Therapeutics Inc said on Thursday their gene therapy helped maintain levels of a vital protein for up to 14 months in patients with a rare genetic disorder in which blood does not clot easily.Pfizer and Sangamo's therapy is one of several treatments being developed for hemophilia A, as an alternative to the current practice that requires regular infusions to replace the missing protein, factor VIII.